Cartesian Therapeutics (RNAC) Profit After Tax (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Profit After Tax for 12 consecutive years, with -$39.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 121.24% year-over-year to -$39.2 million; the TTM figure through Mar 2026 stood at -$151.8 million (down 296.17% YoY), while the FY2025 annual figure was -$130.3 million, down 68.3% from the prior year.
• Profit After Tax rose to -$39.2 million in Q1 2026 per RNAC's latest filing, from -$92.6 million in the prior quarter.
• Across five years, Profit After Tax topped out at $28.8 million in Q1 2022 and bottomed at -$177.7 million in Q4 2023.
• Historically, Profit After Tax has averaged -$25.4 million across 5 years, with a median of -$11.4 million in 2023.
• Annual changes were most pronounced in 2023 — Profit After Tax slumped 3110.64% — and 2024, when it surged 221.51%.
• Cartesian Therapeutics' Profit After Tax stood at $5.9 million in 2022, then plunged by 3110.64% to -$177.7 million in 2023, then surged by 94.23% to -$10.2 million in 2024, then slumped by 803.78% to -$92.6 million in 2025, then jumped by 57.69% to -$39.2 million in 2026.
• Business Quant data shows RNAC's Profit After Tax at -$39.2 million in Q1 2026, -$92.6 million in Q4 2025, and -$35.9 million in Q3 2025.